Cognoa, the leading digital therapeutics company focused on pediatric behavioral health, announced today that renowned pediatrician and 2018 Past President of the American Academy of Pediatrics (AAP), Dr. Colleen Kraft, has joined the company as Senior Medical Director of Clinical Adoption. Dr Kraft’s expertise and experience will be used to assist in the broad adoption of Cognoa’s digital therapeutics by pediatricians to fundamentally enhance the standard of care for children with behavioral conditions, starting with autism.
Better Therapeutics, a developer of prescription digital therapeutics for the treatment of cardiometabolic diseases, today announced an upcoming poster presentation at the Endocrine 2020 conference. The presentation will include data from a pilot study of Better’s software-only prescription digital therapeutic in patients with type 2 diabetes. The conference will take place on March 28-31, at San Francisco’s Moscone Center.
The pilot studied 74 participants with type 2 diabetes and a baseline HbA1c ≥ 7%. Diabetes is defined by an HbA1c value of 6.5% or higher. In addition, study participants had a mean age of 55.2 years, baseline BMI of 34.7 kg/m2, 10.6 years since diagnosis of type 2 diabetes and 72% were female.
Voluntis (Euronext Paris, Ticker: VTX), a leader in digital therapeutics, and Bristol-Myers Squibb Company (NYSE:BMY) today announced a collaboration agreement to create and investigate digital therapeutic solutions that will support cancer patients. Leveraging Theraxium Oncology, Voluntis’ core platform for digital therapeutics in oncology, the collaboration will evaluate potential solutions that will support management of patient symptoms and remote monitoring by healthcare providers.
Welldoc, a leading digital health company revolutionizing chronic disease management, announced today its strategic partnership with Redox Inc., the leading interoperability platform for healthcare data exchange. The partnership will allow providers to receive and review insights about users of the BlueStar® digital health app for diabetes management directly within their EHR at the point of care. With a shared vision to improve health outcomes of patients and alleviate physician burden, Welldoc and Redox are positioned to optimize clinical decision support by making more patient data available in real time. This is critical for patients managing a chronic disease.
Akili Interactive today announced that results from the STARS-ADHD trial of AKL-T01, a digital therapeutic designed to improve attention in children with attention-deficit/hyperactivity disorder (ADHD) were published in The Lancet Digital Health journal. The publication represents the first presentation of complete results from the STARS-ADHD trial, a first-of-its-kind large, randomized, multi-center, controlled study of the company’s flagship technology and the first seminal trial in a series of recent and ongoing studies of the attentional treatment. Results show AKL-T01 improved both objective measures and parent observations of attention and functional impairments.
DarioHealth Corp. (NASDAQ: DRIO), a pioneer in the global digital therapeutics market, announced today the launch of its digital therapeutics solution for managing chronic diseases such as diabetes and hypertension on Albertsons Marketplace.
Albertsons Companies is one of the largest retailers in the United States, with more than 2,000 grocery stores under well-known banners such as Albertsons, Safeway, Vons, Jewel-Osco, Shaw’s, Acme, Tom Thumb, Randalls, United Supermarkets, Pavilions, Star Market, Haggen and Carrs. Through more than 1,700 in-store pharmacies across the country, Albertsons services millions of patients each year.
New data from digital inhalers confirms that exposure to the air pollutant ozone is strongly linked to increased use of inhaled medications for asthma symptoms, according to a new study from CommonSpirit Health; Propeller Health; University of California, Berkeley; and University of California, San Francisco, published in Environment International.
Asthma is one of the most common chronic respiratory diseases in the United States, resulting in more than $82 billion a year in healthcare costs. In the Sacramento and San Joaquin Valleys of California, people have unusually high levels of asthma-related emergency department visits and hospitalizations. This prompted CommonSpirit to study environmental factors that could be worsening asthma symptoms for its patients.
Mental health has become a global epidemic, and employers are quickly becoming aware of how important it is to provide resources for workers who may be struggling.
“We’ve gone through an evolution from where mental health wasn’t being addressed at all within the workplace to a point today where there is a far higher level of awareness,” says Ken Cahill, CEO of SilverCloud Health, a digital mental health company. “But we have to move from that to providing an actionable plan and a solution within the workplace.”
MedRhythms, a Portland, Maine-based digital therapeutics company that uses sensors, software, and music to measure and improve walking, today announced the advancement of its pipeline in multiple sclerosis (MS) and Parkinson’s disease (PD). As part of this effort, MedRhythms has established MS and PD Scientific Advisory Boards that will provide guidance related to the Company’s clinical and research activities in these disease states. Additionally, MR-004, the Company’s pipeline product for walking rehabilitation in MS, will be studied at Cleveland Clinic in a pilot-scale randomized controlled trial to evaluate its safety and efficacy. This trial is made possible by a grant from the Consortium of Multiple Sclerosis Centers (CMSC).